Article

Phase III trial to compare wet AMD drugs

Regeneron Pharmaceuticals Inc. and Bayer HealthCare have initiated a phase III study of a fusion protein anti-vascular endothelial growth factor (VEGF Trap-Eye) in the neovascular form of age-related macular degeneration (wet AMD).

Tarrytown, NY-Regeneron Pharmaceuticals Inc. and Bayer HealthCare have initiated a phase III study of a fusion protein anti-vascular endothelial growth factor (VEGF Trap-Eye) in the neovascular form of age-related macular degeneration (wet AMD).

The study will compare the agent, administered at 4-and 8-week intervals, and ranibizumab (Lucentis, Genentech), administered at 4-week intervals. About 1,200 patients throughout the United States and Canada will be enrolled in the randomized, double-masked study. Patients will be given 0.5-mg and 2-mg doses at 4-week intervals, and 2 mg at 8-week intervals, compared with 0.5 mg of ranibizumab every 4 weeks.

The study hopes patients' vision will improve or lose fewer than 3 lines on an Early Treatment Diabetic Retinopathy Study chart at the end of 1 year.

In an analysis of interim data from the ongoing phase II trial, in which patients were treated with the agent monthly or quarterly, patients demonstrated a statistically significant reduction in retinal thickness and improvement in visual acuity after 12 weeks, compared with baseline.

Regeneron and Bayer are collaborating on the drug development. Bayer will market the drug outside the United States, while Regeneron maintains rights in the United States.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.